LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 2493 | 5505 | 0.4529 | 0.2172 |
BT-20 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1812 | 5505 | 0.3292 | 0.0402 |
BT-20 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 4549 | 5505 | 0.8262 | 0.7514 |
BT-20 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 924 | 5505 | 0.1680 | -0.1905 |
BT-20 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2697 | 5505 | 0.4899 | 0.2701 |
BT-20 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1183 | 5505 | 0.2150 | -0.1232 |
BT-20 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1657 | 890 | 5505 | 0.1618 | -0.1994 |
BT-20 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1176 | 5505 | 0.2136 | -0.1252 |
BT-20 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 673 | 5505 | 0.1224 | -0.2557 |
BT-20 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 4839 | 5505 | 0.8790 | 0.8268 |
BT-20 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 3680 | 5505 | 0.6684 | 0.5256 |
BT-20 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 3529 | 5505 | 0.6410 | 0.4863 |
BT-20 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1646 | 5505 | 0.2990 | -0.0031 |
BT-20 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2213 | 5505 | 0.4020 | 0.1444 |
BT-20 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1283 | 5505 | 0.2332 | -0.0972 |
BT-20 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1008 | 5505 | 0.1831 | -0.1688 |
BT-20 | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2575 | 5505 | 0.4678 | 0.2385 |
BT-20 | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 1657 | 6867 | 5505 | 1.2473 | 1.3538 |
BT-20 | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 3520 | 5505 | 0.6393 | 0.4840 |
BT-20 | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1525 | 5505 | 0.2771 | -0.0344 |
BT-20 | R406 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 2463 | 5505 | 0.4474 | 0.2093 |
BT-20 | Pictilisib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1554 | 5505 | 0.2823 | -0.0270 |
BT-20 | Gefitinib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 4280 | 5505 | 0.7775 | 0.6817 |
BT-20 | Geldanamycin | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1357 | 5505 | 0.2466 | -0.0780 |
BT-20 | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1353 | 5505 | 0.2458 | -0.0791 |